 The preclinical rationale for tauroursodeoxycholic acid TUDCA use in treating patients with amyotrophic lateral sclerosis ALS stems from the demonstration of antioxidant, antiapoptotic and neuroprotective properties of TUDCA in the central nervous system CNS, both in vitro and in vivo models. 